Celsion Corporation (CLSN)
|Net Income (ttm)||-19.56M|
|Day's Range||0.385 - 0.440|
|52-Week Range||0.386 - 3.480|
|Price Target||3.25 (+732.7%)|
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and i... [Read more...]
Financial PerformanceFinancial Statements
According to one analyst, the rating for Celsion stock is "Strong Buy" and the 12-month stock price forecast is 3.25.
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred ...
LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today ann...
Celsion Corporation 's GEN-1 IL-12 Program in Ad vanced Ovarian Cancer to be Featured in Poster Presentation
Balance Sheet Supports Focus o n Immuno-Oncology and Next-Generation Vaccine Initiative
Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, Novem...
LAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announce...
Application A pproval Will Further Extend Current Operating Runway to Over Three Years
Celsion Corporation's GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit
Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions
Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual P resentation Monday, October 18 at 7:30 a.m. Eastern Time
Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual P resentation on Celsion's O ngoing W ork with DNA-based V accines
Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced...
Investigator-Sponsored Research with ThermoDox ® Continues in Multiple Indications
Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities
LAWRENCEVILLE, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces...
E xpands GEN-1 P rogram C ollaboration to Add C linical and C ommercial B atches of I nvestigational V accine
Why investors are watching these 3 penny stocks right now The post Hot Penny Stocks to Add to Your September Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.
Are these penny stocks on your watchlist in August 2021? The post Hot Penny Stocks to Watch Right Now, Have You Heard of These 3?
What you need to know about these 4 penny stocks this week? The post Penny Stocks to Buy This Week?
Celsion Corporation to Hold Second Quarter 2021 Financial Results and Business Update Conference Call on Thursday, Au...
LAWRENCEVILLE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced...
Results of Celsion's OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of ...
Data show d ose - dependent suppression of immun e- suppressive agents
Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of th...
OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted
These three biotech penny stocks all have developed drugs that have shown strong indications of success. The post 3 Biopharma Penny Stocks That Could be Millionaire Makers appeared first on InvestorPlace.
Celsion GmbH Announces Commencement of Enrollment in Oxford University's Phase 1 Study with ThermoDox® and Focused Ul...
LAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company, announc...
Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®
Celsion GmbH will manage current and future cancer studies with Thermo D ox ®
Improvement to the Balance Sheet Leverages Strong Equity Structure
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
Brings extensive biopharmaceutical legal background to the Board
25-year pharmaceutical industry executive brings broad drug development perspective